Can-Fite Biopharma Profit Margin

Can-Fite Biopharma's profit margin stands at -2358.77% as of June 2026. That compares with -1571.07% in the prior-year period — down 50.1% year over year. That is below the Healthcare sector average of 21.34%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Can-Fite Biopharma reported -2358.77% in profit margin versus -1571.07% a year earlier — a 50.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Can-Fite Biopharma sits lower the Healthcare benchmark (21.34%) with a profit margin of -2358.77%. That is roughly 11155.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -2358.77% for Can-Fite Biopharma means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Can-Fite Biopharma's profit margin evolved across reporting periods, while the comparison chart places CANF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.